# MANIFEST-2 (NCT04603495)

> Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04603495
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions: Pelabresib; Ruxolitinib; Placebo
- Enrollment: 430
- Primary outcome: Number of Participants With Splenic Response by Central Radiology Reads at Week 24

## Commentary we found

- YouTube: 61
- Podcasts: 27
- X threads: 21
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=manifest-2-nct04603495

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04603495", "email": "<work email>"}; the inbox owner confirms by the emailed link.